At Stockmatusow.com, my team of traders and investors scan the biotech sector daily, looking for stocks we believe provide excellent trading and investment opportunities. We factor in potential price moving catalyst events along with chart technicals and current news events,…
EDAP: An Undervalued Company With An Alternative Treatment For Prostate Cancer
In doing some fresh scans for 2013, I found a company that has a very small market cap of only $38 million but competes in the very large market of prostate cancer. EDAP TMS SA (EDAP) looks like a very…
BioTech wrap up for December 21st $ALXA $FOLD
$ALXA and $FOLD Commentary, Merry Christmas and a happy new year to everyone!
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Alert: I bought ArQule Inc. $ARQL
ArQule Inc. (ARQL) Price: $2.86 Market Cap: $178.30M My price target opinion into January 13, $4.00 Catalyst: Tivantinib ArQule has advanced into Phase 3 clinical development with its lead product, tivantinib (ARQ 197), an orally available, small molecule that inhibits…
Ziopharma (ZIOP) Trading Thesis
Ziopharm Oncology (ZIOP) is a cancer biotech with pivotal P3 results expected during Q1 2013 for lead pipeline product, ZYMAFOS, in addition to several other compounds in early-mid stages of clinical development and another ongoing P3 trial for ZYMAFOS that…
Osiris Therapeutics (OSIR) Catalyst Trade Thesis
Osiris Therapeutics (OSIR) Osiris expects to have data in hand (final data collection date for primary outcome measure) by the end of this year for the Phase III evaluation of Prochymal (remestemcel-L), which is an adult human stem cells treatment…
Trade alert: I bought bullish chart, target = $10.75
Trade alert: $OSIR P3 data by end of year, bullish chart, target = $10.75 RSI trending: short term cup, downside resistance, decent volume could move near $11. DISCLAIMER: This post is intended for informational and entertainment use…
Synta Pharma: Poised For A Breakout With 4 Near Term Catalysts
Synta Pharmaceuticals Corp. (NASDAQ: SNTA)is a biopharmaceutical company focusing on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug…
